Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Research indicates GLP-1 receptor agonists, like Ozempic, may elevate testosterone levels in men while promoting weight loss. A study presented at ENDO 2025 showed a significant increase in ...

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

Remarkable new findings about the sugar stores in neurons have unlocked an entire new method of treating Alzheimer's disease ...

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 ...

Over a mean 2.2 years, the GLP1-RA group had significantly lower annual rates of acute healthcare utilization per patient (1.52 vs 1.67 events) and all-cause deaths (17.7% vs 20.5%) compared with ...

The findings of this study suggest that patients with GIP/GLP-1 RA prescriptions were less likely to experience opioid overdose and alcohol intoxication than those without such prescriptions. This ...

Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

Before adjustment, for example, the GLP-1 RA group tended to be older (median 74 vs 67) and had more comorbidities like CKD (46.5% vs 33.2%) and coronary artery disease (70.1% vs 58.1%).

Within the subclass of GLP-1 RAs, semaglutide increased the most, from 0.2 to 4.4% from 2018 to 2023. Within one year, tirzepatide, which was approved in 2022, reached 1.3%.

The analysis included 18,016 kidney transplant recipients with diabetes (2013 through 2020) covered by Medicare, of whom 10.9% had at least one GLP-1 RA prescription filled posttransplant.